Investor Presentation

Date: October 30, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558 Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026. Request you to take the same on record. Thank you. Yours faithfully, For Fabtech Technologies Limited Hemant Mohan Anavkar Executive Director DIN: 00150776 Encl.: As mentioned above FAB TECH TECHN OLOGIES LI M I TED Engineering the capability behind the future of healthcare Integrated | Global | Asset Light | Engineering led Pharma | Biotech | Healthcare | Advanced Manufacturing Design & Build Enabling Science Engineering life Investor Presentation - Q2 & H1FY27 Disclaimer This document has been prepared for information purposes only and is not an offer or invitation or recommendation to buy or sell any securities of Fabtech Technologies Ltd, nor shall part, or all, of this document form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities of the Company. This document is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this document is being provided by the Company and is subject to change without notice. The Company relies on information obtained from sources believed to be reliable but does not guarantee its accuracy or completeness. This document contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as "expects" and "anticipates" and words of similar import. Any statement in this document that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the document. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Investor Presentation - Q2 & H1FY27 2 About Us Every vaccine, IV solution, inhaler and Start to Finish Design & Build turnkey 62+ Countries biotech product is made inside a certified, 06 01 provider that designs, engineers, builds and sterile facility – our area of expertise. validates those facilities — for pharma, biotech and healthcare clients worldwide. 2000+ Specialized Installations Build the Caters to pharmaceutical manufacturers, Delivers cleanrooms, HVAC, process capabilities national vaccine institutes, development 500+ Projects Delivered utilities, containment suites and 05 02 finance-backed public health complete Greenfield GMP plants on a that make organizations and programs, and single-point responsibility basis. medicines governments. ₹900+ Cr Order Book (as of 30th Sept 2026) Built a life sciences platform focused on ~75-80% of Revenue from MENA, Operates through local entities across infrastructure manufacturing, 04 03 GCC & ECO Zone markets India, the GCC and Africa, providing us in-house utilities and process machines, strong global references. enabling it to qualify for large-scale biotech tenders. Core systems manufactured in-house under one roof, ensuring control over quality, speed & cost Process Air Water Manufacturing & process Cleanrooms & HVAC - the Purified-water & utility equipment integrated into controlled environment systems engineered to the production line. medicines are made in. pharmacopoeia grade. Investor Presentation - Q2 & H1FY27 3 Performance Highlights Investor Presentation - Q2 & H1FY27 4 Business Highlights Revenue Recovery Expected in H2 New Market Entry Strong EBITDA Growth Revenue and profitability are expected to The Company enters a CIS country with a EBITDA (incl. other income) more than improve as planned project milestones new turnkey design-and-build project. doubled QoQ, up 110% to ₹155.7 mn in Q2 translate into execution during H2 FY27 FY27. Improved Profitability Outlook International Industry Engagement Management remains confident of achieving Participation in CPHI Milan 2026 provided an its FY27 Adjusted PAT* margin objective of opportunity to engage with pharmaceutical 8–9%. industry stakeholders and explore potential project opportunities *Adjusted PAT excludes exceptional items Investor Presentation - Q2 & H1FY27 5 Operational Update Business resilience & momentum Order book & growth visibility H1 navigated geopolitical uncertainty and freight Healthy order book: Rs. 900 crore (2.2x FY26 Revenue) volatility across GCC markets. Additional prospective orders from Africa and Saudi Arabia: Rs. 800-850 crore. The existing order position provides meaningful Q2 UAE operations demonstrated remarkable progress visibility over the next 12 months. and strong order traction despite regional conditions. Continuity of operations, deliveries and customer commitments was maintained despite higher costs. Africa is expected to be a significant contributor to H2 project execution and revenue. Installation continued with enhanced security and Accelerate project delivery and business development across Africa protective measures for site teams, resulting in and the UAE while managing Saudi project timelines. significant additional installation costs. Advance capabilities in cell and gene therapy facilities, other high- technology projects and data-centre infrastructure. Africa initiatives are gaining momentum, including cell and gene therapy (CGT) and other advanced- technology facility projects. Maintain disciplined execution, cost control and customer commitments. Investor Presentation - Q2 & H1FY27 6 Consolidated Income Statement – Q2/H1 FY27 Particulars (INR Mn) Q2FY27 Q1FY27 Q2FY26 QoQ% H1FY27 H1FY26 Revenue From Operations 920.9 749.8 1,214.8 22.8 1,670.7 1,894.9 Other Income 54.5 31.7 28.0 72.2 86.2 37.4 Total Income 975.4 781.5 1,242.8 24.8 1,756.9 1,932.3 Total Expenditure 819.7 707.4 910.3 15.9 1,527.1 1,652.5 EBITDA 155.7 74.1 332.5 110.0 229.8 279.8 EBITDA Margin (%) 16.0 9.5 26.8 647 bps 13.1 14.5 Reported PAT 150.2 42.1 281.1 256.9 192.4 219.8 Reported PAT Margin (%) 16.3 5.6 23.1 1,070 bps 11.5 11.6 Adjusted PAT** 84.3 42.1 281.1 99.1 126.5 202.1 Adjusted PAT Margin 9.2 5.6 23.1 354 bps 7.6 10.7 Earnings Per Share (Rs)* 3.38 0.95 8.68 4.33 6.79 **Adjusted PAT excludes exceptional items (net of tax) of INR 65.9 Mn in Q2 & H1 FY27 & INR 17.7 Mn in H1 FY26. *The Company issued approximately 1.20 crore equity shares through its IPO in October 2025. Investor Presentation - Q2 & H1FY27 7 Strategic Priorities Accelerate project delivery and business Advance capabiliti [Showing first 8,000 characters — download PDF for full document]